A carregar...
Reducing Palivizumab Dose Requirements Through Rational Dose Regimen Design
Palivizumab for respiratory syncytial virus (RSV) immunoprophylaxis in premature infants poses a significant economic challenge. Although standard dosing of palivizumab results in unnecessary drug accumulation without additional clinical benefit, some clinicians have moved outside of evidence‐based...
Na minha lista:
| Publicado no: | CPT Pharmacometrics Syst Pharmacol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6363066/ https://ncbi.nlm.nih.gov/pubmed/30426719 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12364 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|